This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
26 Apr 2016

Catalent wins award at INTERPHEX for its OptiForm Solution Suite platform

OptiForm Solution Suite — designed to efficiently and rapidly help solve complex bioavailability challenges for early-stage molecules, using a unique toolkit of bioavailability enhancing technologies.

Catalent Pharma Solutions has won the ‘Editor’s Choice’ category at the annual INTERPHEX Awards, for its OptiForm Solution Suite platform.

OptiForm Solution Suite is an integrated, fixed price service, designed to efficiently and rapidly help solve complex bioavailability challenges for early-stage molecules, using a unique toolkit of bioavailability enhancing technologies, including comprehensive molecule characterization and unique salt screening assessment combined with parallel processing up to four superior formulation technologies. OptiForm Solution Suite matches the best formulation technologies to the molecule, and utilizes an accelerated parallel screening and development approach, based on rigorous science and best-in-class scientific expertise, in just 12 weeks.

“In the early stages of drug development, it is vital to achieve a suitable formulation so that animal pharmacokinetic studies can be initiated quickly,” commented Julien Meissonnier, Vice President, Science & Technology. “The combination of a wide array of innovative formulation technology options, and rapid screening and selection techniques available through the OptiForm Solution Suite can help overcome these challenges.”

Catalent’s OptiForm Solution Suite platform was presented at the INTERPHEX opening ceremony, on Tuesday, 26 April 26. The convention is currently taking place at The Javits Center, New York City, and runs until Thursday 28 April.

Related News